Skip to main content
letter
. 2023 Jul 26;13(1):113. doi: 10.1038/s41408-023-00885-9

Table 2.

Affected patients and MAHA/TMA characteristics.

Patient no. Age + sex MAHA/TMA Cycle onset no. Schistocytes Hb Platelets LDH Retic Haptoglobin Nadir Bilirubin Other End organ damage With infection No. of episodes
15 84 M MAHA 2 Yes 88 87 338 303 NA 12 - Nil - 1
16 65 M MAHA 3 Yes 101 49 458 219 NA 10 - Nil - 1
21 56 M MAHA (subTMA) 7 Yes 90 47 380 NA NA 7 - AKI Cr 86–140 Influenza A 1
29 64 F MAHA 4 Yes 120 76 310 NA NA 9 - Nil Rhinovirus 1
30 72 M MAHA 4 Yes 94 89 269 245 Undetectable 12 Urine haemosiderin Nil - 2
36 81 F MAHA (subTMA) 7 Yes 108 123 257 192 NA 4 - AKI Cr 176–225 - 2
TMA 12 Yes 66 120 313 164 Undetectable 7 Low C3, normal C4 Renal -
37 81 M MAHA (subTMA) 3 Yes 89 72 255 NA Low 0.2 8 - AKI Cr 111–138 - 2
38 70 F MAHA (subTMA) 5 Yes 92 66 417 NA NA 4 - AKI Cr 90–117 RSV 2
TMA 17 Yes 92 27 987 12 Undetectable 11 - Renal, Cardiac Influenza A
39 64 M MAHA (subTMA) 6 Yes 81 68 415 NA NA 14 - AKI Cr 119–216 - 1
41 82 M MAHA 6 Yes 94 100 507 208 NA 11 - Nil - 2
44 77 M MAHA 7 Yes 101 58 344 91 Low 0.48 6 - Nil - 1

Units and normal ranges—Haemoglobin (Hb) males 130–170 g/L and females 120–150 g/L, Platelets 150–400 × 109/L, LDH < 250 U/L, Reticulocyte count 50–100 × 109/L, Haptoglobin 0.5–2.6 g/L, Bilirubin < 20 µmol/L, Creatinine (Cr) males 60–110 µmol/L, females 45–90 µmol/L.

NA not available, sub TMA subclinical TMA (in bold).